Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases, and Amyotrophic Lateral Sclerosis Research.
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
Advancing multiple sclerosis management in older adults
Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials
Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
The impact of relapse definition and measures of durability on MS clinical trial outcomes
How patients with multiple sclerosis acquire disability
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum
Serum neurofilament light-chain (sNfL) levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis (RRMS) patients in the CombiRx trial (2410)
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis
Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Early complement genes are associated with visual system degeneration in multiple sclerosis
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
A Framework of Care in Multiple Sclerosis, Part 2
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Recommendations for observational studies of comorbidity in multiple sclerosis
The challenge of comorbidity in clinical trials for multiple sclerosis
Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?
Relapses in multiple sclerosis: Relationship to disability
Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data
Effect of in‐painting on cortical thickness measurements in multiple sclerosis: A large cohort study